Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.

B. T. Zafonte, J. Hulit, D. F. Amanatullah, C. Albanese, C. Wang, E. Rosen, A. Reutens, Joseph A. Sparano, M. P. Lisanti, R. G. Pestell

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast cancer therapy are herein reviewed. Improved understanding of the biology of breast cancer has led to more specific "targeted therapies" directed at biological processes that are selectively deregulated in the cancerous cells. Examples include tamoxifen for estrogen receptor positive tumors and imunoneutralizing antibodies such as trastuzumab for Her2/neu overexpressing tumors. Other novel anticancer agents such as paclitaxel, a microtubule binding molecule, and flavopiridol, a cyclin dependent kinase inhibitor, exert their anticancer effects by inhibiting cell cycle progression.

Original languageEnglish (US)
JournalFrontiers in Bioscience
Volume5
StatePublished - 2000

Fingerprint

alvocidib
Tumors
Cell Cycle
Cells
Breast Neoplasms
Neoplasm Antibodies
Chemotherapy
Cyclin-Dependent Kinases
Cell proliferation
Tamoxifen
Paclitaxel
Estrogen Receptors
Antineoplastic Agents
Surgery
Machinery
Intercellular Signaling Peptides and Proteins
Steroids
Irradiation
Biological Phenomena
Neoplasms

Cite this

Zafonte, B. T., Hulit, J., Amanatullah, D. F., Albanese, C., Wang, C., Rosen, E., ... Pestell, R. G. (2000). Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Frontiers in Bioscience, 5.

Cell-cycle dysregulation in breast cancer : breast cancer therapies targeting the cell cycle. / Zafonte, B. T.; Hulit, J.; Amanatullah, D. F.; Albanese, C.; Wang, C.; Rosen, E.; Reutens, A.; Sparano, Joseph A.; Lisanti, M. P.; Pestell, R. G.

In: Frontiers in Bioscience, Vol. 5, 2000.

Research output: Contribution to journalArticle

Zafonte, BT, Hulit, J, Amanatullah, DF, Albanese, C, Wang, C, Rosen, E, Reutens, A, Sparano, JA, Lisanti, MP & Pestell, RG 2000, 'Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.', Frontiers in Bioscience, vol. 5.
Zafonte BT, Hulit J, Amanatullah DF, Albanese C, Wang C, Rosen E et al. Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle. Frontiers in Bioscience. 2000;5.
Zafonte, B. T. ; Hulit, J. ; Amanatullah, D. F. ; Albanese, C. ; Wang, C. ; Rosen, E. ; Reutens, A. ; Sparano, Joseph A. ; Lisanti, M. P. ; Pestell, R. G. / Cell-cycle dysregulation in breast cancer : breast cancer therapies targeting the cell cycle. In: Frontiers in Bioscience. 2000 ; Vol. 5.
@article{12a573ba828d4bedbb175718d7160a0a,
title = "Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycle.",
abstract = "Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast cancer therapy are herein reviewed. Improved understanding of the biology of breast cancer has led to more specific {"}targeted therapies{"} directed at biological processes that are selectively deregulated in the cancerous cells. Examples include tamoxifen for estrogen receptor positive tumors and imunoneutralizing antibodies such as trastuzumab for Her2/neu overexpressing tumors. Other novel anticancer agents such as paclitaxel, a microtubule binding molecule, and flavopiridol, a cyclin dependent kinase inhibitor, exert their anticancer effects by inhibiting cell cycle progression.",
author = "Zafonte, {B. T.} and J. Hulit and Amanatullah, {D. F.} and C. Albanese and C. Wang and E. Rosen and A. Reutens and Sparano, {Joseph A.} and Lisanti, {M. P.} and Pestell, {R. G.}",
year = "2000",
language = "English (US)",
volume = "5",
journal = "Frontiers in Bioscience - Landmark",
issn = "1093-9946",
publisher = "Frontiers in Bioscience",

}

TY - JOUR

T1 - Cell-cycle dysregulation in breast cancer

T2 - breast cancer therapies targeting the cell cycle.

AU - Zafonte, B. T.

AU - Hulit, J.

AU - Amanatullah, D. F.

AU - Albanese, C.

AU - Wang, C.

AU - Rosen, E.

AU - Reutens, A.

AU - Sparano, Joseph A.

AU - Lisanti, M. P.

AU - Pestell, R. G.

PY - 2000

Y1 - 2000

N2 - Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast cancer therapy are herein reviewed. Improved understanding of the biology of breast cancer has led to more specific "targeted therapies" directed at biological processes that are selectively deregulated in the cancerous cells. Examples include tamoxifen for estrogen receptor positive tumors and imunoneutralizing antibodies such as trastuzumab for Her2/neu overexpressing tumors. Other novel anticancer agents such as paclitaxel, a microtubule binding molecule, and flavopiridol, a cyclin dependent kinase inhibitor, exert their anticancer effects by inhibiting cell cycle progression.

AB - Breast cancer is the most commonly diagnosed cancer in American women. The underlying mechanisms that cause aberrant cell proliferation and tumor growth involve conserved pathways, which include components of the cell cycle machinery. Proto-oncogenes, growth factors, and steroids have been implicated in the pathogenesis of breast cancer. Surgery, local irradiation, and chemotherapy have been the mainstay of treatment for early and advanced stage disease. Potential targets for selective breast cancer therapy are herein reviewed. Improved understanding of the biology of breast cancer has led to more specific "targeted therapies" directed at biological processes that are selectively deregulated in the cancerous cells. Examples include tamoxifen for estrogen receptor positive tumors and imunoneutralizing antibodies such as trastuzumab for Her2/neu overexpressing tumors. Other novel anticancer agents such as paclitaxel, a microtubule binding molecule, and flavopiridol, a cyclin dependent kinase inhibitor, exert their anticancer effects by inhibiting cell cycle progression.

UR - http://www.scopus.com/inward/record.url?scp=0034543419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034543419&partnerID=8YFLogxK

M3 - Article

C2 - 11102317

AN - SCOPUS:0034543419

VL - 5

JO - Frontiers in Bioscience - Landmark

JF - Frontiers in Bioscience - Landmark

SN - 1093-9946

ER -